Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?

Abstract

Radiation recall syndrome (RRS) characterized by an inflammatory reaction within a previously irradiated volume has been reported after chemotherapy administration, few reports being made after administration of cetuximab and bevacizumab [1, 2]. Here, we report RRS occurring during mTOR (mammalian target of rapamycin) kinase inhibitors administration. Known common toxic effects of these targeted therapies are rash, stomatitis, fatigue, and metabolic disorders.